Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

1
Player Avatar majakblue (< 20) Submitted: 4/14/2007 3:19:13 PM : Underperform Start Price: $6.19 DYAX Score: +24.62

Yeah, yeah, yeah, lets see if any of their candidates get past large scale phase III trials. Lets see if the patients have kidneys and liver left afterwards.

Featured Broker Partners


Advertisement